UTRECHT, THE NETHERLANDS, 17 October 2012 – MILabs, B.V. the Netherlands‐based innovator and manufacturer of pre‐clinical SPECT/PET/CT imaging devices used in biological and pharmaceutical research today announces the new Quick‐Start SPECT (U‐SPECTQS) system specially designed for research institutions seeking a reliable and high‐performance, yet cost‐effective molecular imaging solution. Due to its simplified set‐up U‐SPECTQS is extremely user friendly. The system can be equipped with a dedicated or versatile high performance collimator resulting in significant savings.
U‐SPECTQS has the further benefit of field‐upgradeability to the more versatile U‐SPECT/CT, or VECTor/CT as funding and research applications expand. VECTor/CT expands imaging capabilities to 0.25 mm SPECT, full 0.75 mm PET and simultaneous SPECT/PET for a wide range of standard and highly advanced research applications.
Please contact MILabs for further details regarding how the new Quick‐Start opportunity can benefit your institution and can be best applied to your specific research needs.
About MILabs
MILabs provides high‐end pre‐clinical molecular imaging solutions (SPECT/PET/CT) for biomedical and pharmaceutical research. Today these systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as cancer, cardiac and neurodegenerative diseases, depression and diabetes. U‐SPECT/CT provides the fastest, most sensitive and highest resolution small‐animal SPECT currently available. Recently MILabs introduced VECTor and VECTor/CT providing extremely user friendly, fully integrated and simultaneous ultra‐high resolution SPECT/PET.